- |||||||||| AMXI-5001 / AtlasMedx
Journal, Combination therapy: Novel dual action PARP and microtubule polymerization inhibitor AMXI-5001 powerfully inhibits growth of esophageal carcinoma both alone and in combination with radiotherapy. (Pubmed Central) - Feb 7, 2024
We found that AMXI-5001 was the most potent growth inhibitor of 8 out of 9 different esophageal carcinoma cell lines compared to other clinically available PARP inhibitors, Olaparib, Niraparib, Rucaparib, and Talazoparib...To further assess AMXI-5001's potential as a therapeutic for esophageal carcinoma we evaluated the effect of AMXI-5001 in combination with standard chemotherapy agents, Cisplatin and 5 Fluorouracil...Compared to vehicle control, and those treated with either AMXI-5001 alone or radiation alone, mice treated with both AMXI-5001 and radiation had significant tumor response. In conclusion, AMXI-5001 is an orally bioavailable dual-action PARP and microtubule polymerization inhibitor that holds promise in the treatment of esophageal carcinoma.
- |||||||||| AMXI-5001 / AtlasMedx
Enrollment change, Trial completion date, Trial primary completion date, Metastases: ATLAS-101: A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies (clinicaltrials.gov) - Jul 21, 2023
P1/2, N=122, Recruiting,
In conclusion, AMXI-5001 is an orally bioavailable dual-action PARP and microtubule polymerization inhibitor that holds promise in the treatment of esophageal carcinoma. N=80 --> 122 | Trial completion date: Jan 2023 --> Jan 2025 | Trial primary completion date: Jan 2023 --> Jan 2025
- |||||||||| AMXI-5001 / AtlasMedx
Journal, BRCA Biomarker, PARP Biomarker: AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. (Pubmed Central) - Sep 10, 2020
AMXI-5001 resulted in superior anti-tumor effects compared to either single agent (PARP or microtubule) inhibitor or combination with both agents. AMXI-5001 will enter clinical trial testing soon and represents a promising, novel first in class dual PARP1/2 and microtubule polymerization inhibitor that delivers continuous and synchronous one-two punch cancer therapy with one molecule.
|
